GeneDx Holdings Corp reports results for the quarter ended March 31 - Earnings Summary

GeneDx Holdings

30/04/2025 14:31

GeneDx Holdings Corp WGS.OQ reported quarterly adjusted earnings of 27 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -33 cents.  The mean expectation of six analysts for the quarter was for earnings of 6 cents per share. Wall Street expected results to range from 1 cents to 11 cents per share.

Revenue rose 40.3% to $85.76 million from a year ago; analysts expected $79.47 million.

GeneDx Holdings Corp's reported EPS for the quarter was a loss of 23 cents​.

The company reported a quarterly loss of $6.53 million.

GeneDx Holdings Corp shares had risen by 32.1% this quarter and gained 52.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 11.5% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for GeneDx Holdings Corp is $109.50

This summary was machine generated from LSEG data April 30 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
0.06
0.27
Beat
Dec. 31 2024
0.16
0.62
Beat
Sep. 30 2024
-0.21
0.04
Beat
Jun. 30 2024
-0.30
-0.10
Beat